LUPUS THERAPEUTIC MARKET ANALYSIS

Lupus Therapeutic Market, By Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Biologics, Antimalarial Drugs, Corticosteroids, and Others), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On March 14, 2024, Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus.
In September 2022, Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company, announced that the European Commission (EC) had approved Lupkynis (voclosporin) in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
In August 2021, AstraZeneca, a global pharmaceutical company, announced that the U.S. Food and Drug Administration approved Saphnelo (anifrolumab-fnia), a type I interferon (type I IFN) receptor antagonist, for treating moderate to severe systemic lupus erythematosus (SLE) in adult patients who are receiving standard therapy.
In December 2020, GSK plc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.